Keyword: Ozempic (semaglutide)
Eli Lilly is wasting no time looking for growth avenues for GLP-1 contender Trulicity. And if new data are any indication, it may have just found one.
Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts.
Highly anticipated phase 3 results for Novo Nordisk’s semaglutide, are here, and rival Eli Lilly's investors are taking note.
Eli Lilly says it isn't afraid of new competition to diabetes drug Trulicity from Novo Nordisk’s newly launched weekly GLP-1, Ozempic.
Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
Novo's vaunted Victoza follow-up is here as the FDA approved Ozempic, formerly known as semaglutide.
Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.
AstraZeneca is hoping a new formulation of Bydureon will give the med some competitive firepower against a field of tough rivals.
With an FDA committee nod, Novo Nordisk is one step closer to rolling out its key diabetes drug semaglutide—and launch preps are underway.
FDA reviewers flagged data on cardiovascular benefits—and potential eye risks—posed by Novo Nordisk's semaglutide, up for approval later this year.